Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:03 PM ET 10-Q
Financial Results Gulfport Energy Corp GPOR ▶ Call

Gulfport Energy Q3 2026 Results: Net Income $96.4M, Down 13.5% YoY

Gulfport Energy Corporation reported 17,412,032 shares of common stock outstanding as of October 29, 2026. The filing highlights the company's continued operations in the Utica and SCOOP plays, supported by a senior secured reserve-based revolving credit facility and senior notes due in 2026 and 2029.

Key figure
Net income $96.4M · -13.5% YoY
4:03 PM ET 10-Q
Financial Results Shift4 Payments, Inc. FOUR

Shift4 Payments Q3 2026 Results: Net Income $38M, Up 35.7% YoY

Shift4 Payments reported gross revenue of $1.32 billion for Q3 2026, a 12% increase year-over-year, though net income attributable to common stockholders decreased to $28 million for the first nine months of 2026 compared to $54 million in 2025. The company's balance sheet shows a significant increase in cash to $1.24 billion and total assets reaching $9.47 billion as of September 30, 2026.

Key figure
Net income $38M · +35.7% YoY
4:03 PM ET Form 4
Insider Selling Kforce Inc KFRC

Kforce Insider David L. Dunkel Sells $175K of Stock

David L. Dunkel sold 3,000 shares of Kforce Inc at $58.10 to $59.10 a share (average $58.31) in 4 transactions, worth $175K in total between Nov 3, 2026 and Nov 4, 2026. Shares held after the trade: 503,329 (-0.1%).

Value
$175K
Shares
3,000
Average price
$58.31
Holding change
-0.1%
Trade date
Nov 3, 2026 to Nov 4, 2026
4:03 PM ET 8-K
Financial Results Blink Charging Co. BLNK

Blink Charging Financial Results

Blink Charging reported Q3 2026 financial results, achieving its first-ever positive quarterly Adjusted EBITDA of $0.2 million, one quarter ahead of target. Total revenue was $18.4 million, a 32% decrease year-over-year, primarily due to portfolio rationalization and the divestiture of its car-sharing business.

Term
Q3 2026

“Achieving positive adjusted EBITDA a quarter ahead of our target is a monumental milestone and it reflects the discipline we have built across Blink over the past eighteen months.”

Mike Battaglia, Chairman and CEO

“Delivering positive adjusted EBITDA of $0.2 million in the third quarter, compared with a $(7.3) million loss a year ago, is a testament to our focus on operational efficiency and cost management.”

Michael Bercovich, Chief Financial Officer
4:03 PM ET 10-Q
Financial Results Bruker Corp BRKR

Bruker Q3 2026 Results: Net Loss of $112M, Loss Widens

Bruker Corporation reported a consolidated net loss of $109.7 million for the third quarter of 2026, compared to a loss of $58.5 million in the prior year period, primarily driven by a $174.5 million goodwill impairment charge. Despite the net loss, total revenue grew slightly to $874.0 million from $860.5 million year-over-year, supported by growth in service and other revenue.

Key figure
Net loss $112M
4:03 PM ET 10-Q
Financial Results Nutex Health Inc. NUTX

Nutex Health Q3 2026 Results: Net Income $40.2M, Down 27.4% YoY

Nutex Health Inc. reported a net income attributable to the company of $152.9 million for the nine months ended September 30, 2026, a significant increase from $59.0 million in the prior year period. Despite a decrease in total revenue from $723.6 million to $644.9 million, the company achieved higher operating income due to a substantial reduction in stock-based compensation expenses.

Key figure
Net income $40.2M · -27.4% YoY
4:03 PM ET 8-K
Financial Results Biodesix Inc BDSX

Biodesix Financial Results

Biodesix reported Q3 2026 total revenue of $24.0 million, a 10% year-over-year increase driven by a 16% rise in Diagnostic Testing revenue. Despite the growth, the company revised its full-year 2026 revenue guidance downward to $101-$103 million, citing slower-than-expected sales representative contributions and seasonality.

Term
Q3 2026

“Biodesix delivered another quarter of year-over-year growth, with total revenue increasing 10%, Diagnostic Testing revenue increasing 16%, test volumes increasing 24%, and gross margin remaining strong at 81%. However, our growth was below our expectations, and we understand the principal drivers: fewer contributing sales representatives than planned limited new physician and account growth; greater-than-anticipated seasonality, primarily in primary care, reduced ordering frequency among otherwise stable base customers; and delays in external customer dependencies postponed the start of Development Services projects and the associated revenue recognition.”

Scott Hutton, Chief Executive Officer

“The factors that impacted the quarter were largely execution and timing related rather than a change in demand, clinical utility, or market opportunity. We have identified the drivers, taken corrective actions, and entered the fourth quarter with a larger sales organization positioned for improved execution.”

Scott Hutton, Chief Executive Officer
4:03 PM ET 10-Q
Financial Results Grayscale Bittensor Trust (TAO) GTAO

Grayscale Bittensor Trust Q3 2026 Results: Turns Profitable, Net Income $4.87M

Grayscale Bittensor Trust (TAO) reported a significant increase in net assets to $17.7 million as of September 30, 2026, driven by $6.5 million in capital share issuances and $3.2 million in net increase from operations. The Trust's Principal Market NAV per Share rose to $5.66 from $4.24 at the end of 2025, despite ongoing net investment losses due to the Sponsor's Fee.

Key figure
Net income $4.87M
4:03 PM ET 8-K
Financial Results Iren Ltd IREN

Iren Financial Results

IREN reported Q1 FY27 financial results with total revenue increasing 66% sequentially to $228 million, driven by AI Cloud revenue nearly tripling to $200 million. The company reported a net loss of $263 million but achieved positive Adjusted EBITDA of $66 million, while noting its $4 billion ARR target is now expected by January or February 2027.

“This quarter Horizon 1 went into service for Microsoft with NVIDIA Exemplar status, AI Cloud revenue nearly tripled to $200 million, and operating ARR doubled to a billion. The more than $4 billion of contracted ARR is funded and now targeted for January, after a customer-requested design change and supplier timing moved it from year-end; it may extend to the end of February.”

Daniel Roberts, Co-Founder and Co-CEO of IREN
4:03 PM ET 10-Q
Financial Results Perdoceo Education Corp PRDO

Perdoceo Education Q3 2026 Results: Net Income $44.4M, Up 11.4% YoY

Perdoceo Education Corp reported a net income of $44.4 million for the third quarter of 2026, up from $39.9 million in the prior year period, driven by a 1.9% increase in total revenue. For the first nine months of 2026, net income reached $146.3 million compared to $124.6 million in 2025, reflecting improved operating margins and higher interest income. The company maintained a strong liquidity position with $776.9 million in cash and short-term investments as of September 30, 2026.

Key figure
Net income $44.4M · +11.4% YoY
4:03 PM ET 10-Q
Financial Results Advance Auto Parts Inc AAP

Advance Auto Parts Q3 2026 Results: Turns Profitable, Net Income $15M

Advance Auto Parts reported net sales of $2,012 million for the twelve weeks ended October 10, 2026, with a net income of $15 million compared to a net loss in the prior year period. The company's forty-week performance showed significant improvement in operating income, reaching $218 million compared to an operating loss of $87 million in 2025.

Key figure
Net income $15M
4:03 PM ET 8-K
Dividend Smart Sand, Inc. SND

Smart Sand Dividend

Smart Sand's Board of Directors has declared a special cash dividend of $0.05 per share of common stock. The dividend is payable on November 30, 2026, to stockholders of record as of November 18, 2026. The company noted it has returned approximately $14 million to shareholders year-to-date through dividends and buybacks.

4:03 PM ET 10-Q
Financial Results First Busey Corp BUSE

First Busey Q3 2026 Results: Net Income $55.8M, Down 2.2% YoY

For the third quarter of 2026, First Busey Corporation reported net interest income of $153.1 million and total noninterest income of $40.4 million. The company's balance sheet shows total assets of $18.6 billion, with a notable increase in cash and cash equivalents to $883.1 million compared to $280.2 million at year-end 2025.

Key figure
Net income $55.8M · -2.2% YoY
4:03 PM ET 8-K
Financial Results Bill Holdings, Inc. BILL

Bill Holdings Financial Results

BILL Holdings reported first quarter fiscal 2027 results with total revenue of $353.8 million, up 13% year-over-year, and core revenue of $316.4 million. The company noted a voluntary change in accounting principle effective July 1, 2026, which now classifies card rewards as a reduction of revenue rather than a sales and marketing expense.

Term
Q1 2027

“AI is changing what’s possible for us, and it shows in our product velocity: five new launches this quarter, and a Visa pilot built in four weeks. We’re well positioned to serve the millions of businesses that still need help simplifying their finances.”

René Lacerte, BILL CEO and Founder

“In Q1, we delivered 14% core revenue growth, significantly expanded our operating margin, and achieved a Rule of 40 score of 51. With a durable business model, a leaner organization, and an integrated platform serving a large market, we are focused on executing with discipline.”

Rohini Jain, BILL Chief Financial Officer
4:03 PM ET 10-Q
Financial Results Mach Natural Resources LP MNR ▶ Call

Mach Natural Resources Q3 2026 Results: Turns Profitable, Net Income $10.2M

Mach Natural Resources LP reported 170,395,787 common units outstanding as of October 30, 2026, and is classified as an accelerated filer and an emerging growth company. The filing outlines a transition to a new senior secured revolving credit agreement dated February 27, 2025, and provides definitions for key performance metrics such as Adjusted EBITDA and PV-10.

Key figure
Net income $10.2M
4:03 PM ET 10-Q
Financial Results Adtran Holdings, Inc. ADTN

Adtran Holdings Q3 2026 Results: Net Loss of $9.23M, Loss Narrows

ADTRAN Holdings, Inc. reported 81,495,825 shares of common stock outstanding as of October 31, 2026. The filing highlights significant risks including indebtedness, material weaknesses in internal control over financial reporting, and ongoing inflationary pressures impacting profitability.

Key figure
Net loss $9.23M
4:03 PM ET 8-K
Financial Results Keros Therapeutics, Inc. KROS

Keros Therapeutics Financial Results

Keros Therapeutics reported third quarter 2026 financial results, highlighted by a net income of $14.2 million compared to a net loss in the prior year, primarily due to revenue recognition from its license agreement with Takeda. The company also announced the first patient dosed in its Phase 2 trial of rinvatercept for DMD and expects its $259.5 million cash balance to fund operations into the second half of 2028.

“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-β biology to develop potential new treatments for patients. We remain focused on disciplined execution of our strategic priorities as we work to advance our programs and build on the potential of our pipeline.”

Jasbir S. Seehra, Ph.D., President and Chief Executive Officer
4:03 PM ET 8-K
Financial Results Voyager Therapeutics, Inc. VYGR

Voyager Therapeutics Financial Results

Voyager Therapeutics reported third quarter 2026 financial results, ending the period with $132 million in cash and extending its projected runway into Q2 2028. The company highlighted progress in its Alzheimer’s disease pipeline, with clinical data readouts for VY7523 expected in Q4 2026 and patient dosing for VY1706 anticipated in the coming months.

“There is strong momentum behind our two tau-targeted Alzheimer’s disease programs, and we expect to report PET imaging data from our VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with our lead gene therapy VY1706 in the next few months.”

Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager

“During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028. This strengthens our position as we approach key upcoming milestones.”

Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager
4:03 PM ET 8-K
Financial Results Conduent Inc CNDT

Conduent Financial Results

Conduent reported Q3 2026 revenue of $534 million and a net loss of $49 million, while reaffirming its full-year 2026 outlook. The company highlighted progress on its ASCEND transformation plan, identifying $106 million of its $120 million cost-savings target and completing a $447 million revolving credit facility refinancing.

Term
Q3 2026

“In the third quarter, we continued to make progress in improving Conduent’s operating performance. Adjusted EBITDA increased year-over-year and sequentially, and we are reaffirming our full-year 2026 outlook.”

Harsha V. Agadi, Chief Executive Officer

“ASCEND 2026–2028 is our framework for turning this transformation into sustained performance. We are standardizing our operations and infrastructure, specializing in core solutions where we can lead and win, and scaling our go-to-market capabilities around priority industries and opportunities.”

Harsha V. Agadi, Chief Executive Officer
4:03 PM ET 8-K
Financial Results TransMedics Group, Inc. TMDX

TransMedics Group Financial Results

TransMedics reported record third-quarter 2026 revenue of $203.0 million, a 41% increase year-over-year, driven by strong growth in both product and service revenue. The company achieved net income of $17.1 million and raised its full-year 2026 revenue guidance to a range of $764 million to $774 million.

“The third quarter of 2026 was the strongest in TransMedics’ history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.”

Waleed Hassanein, MD, President and Chief Executive Officer

“We enter 2027 with strong momentum and a robust set of growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped heart and lung segments, with two shots on goal in each through OCS and CHOPS.”

Waleed Hassanein, MD, President and Chief Executive Officer
4:03 PM ET 10-Q
Financial Results Expensify, Inc. EXFY ▶ Call

Expensify Q3 2026 Results: Net Loss of $3.33M, Loss Widens

Expensify, Inc. reported total assets of $190.3 million as of September 30, 2026, a slight increase from $186.0 million at the end of 2025. The company maintains a diverse capital structure with Class A, LT10, and LT50 common stock, and is currently classified as an accelerated filer and a smaller reporting company.

Key figure
Net loss $3.33M
4:03 PM ET 8-K
Financial Results Corvus Pharmaceuticals, Inc. CRVS

Corvus Pharmaceuticals Financial Results

Corvus Pharmaceuticals reported third quarter 2026 financial results and provided a business update on its soquelitinib clinical programs. The company ended the quarter with $202.9 million in cash and marketable securities, which is expected to provide a financial runway into the second quarter of 2028.

“We continue to drive the science and advance the breadth of potential clinical indications for ITK inhibition with soquelitinib. Our Phase 3 PTCL and Phase 2 atopic dermatitis clinical trials are on track and there has been strong interest in our new hidradenitis suppurativa trial. We also are making good progress towards initiating a unique asthma trial that will include both T2 and non-T2 patients by Q1 2027. We believe soquelitinib has the potential to be effective in both types of asthma patients based on its mechanism of action affecting Th2, Th17 and T regulatory cells, which we will be closely analyzing in our hidradenitis suppurativa trial. Taken altogether, we are positioned for a series of potentially significant data milestones across our soquelitinib development pipeline in 2027.”

Richard A. Miller, M.D., co-founder, president and chief executive officer
4:03 PM ET 10-Q
Financial Results Verastem, Inc. VSTM

Verastem Q3 2026 Results: Net Loss of $74.7M, Loss Narrows

Verastem reported Q3 2026 net product revenue of $24.0 million, a significant increase from $11.2 million in the prior year, driven by AVMAPKI FAKZYNJA CO-PACK sales. Despite a GAAP net loss of $74.7 million, the company strengthened its balance sheet with a $250 million follow-on offering in October, extending its cash runway into the first half of 2028.

Key figure
Net loss $74.7M
4:02 PM ET 10-Q
Financial Results Power Integrations Inc POWI

Power Integrations Q3 2026 Results: Turns Profitable, Net Income $18.3M

Power Integrations reported net revenue of $125.5 million for the third quarter of 2026, an increase from $118.9 million in the prior year period. The company returned to profitability with a net income of $18.3 million compared to a net loss of $1.4 million in Q3 2025, despite incurring $6.2 million in restructuring charges earlier in the year.

Key figure
Net income $18.3M
4:02 PM ET 10-Q
Financial Results Voyager Therapeutics, Inc. VYGR

Voyager Therapeutics Q3 2026 Results: Net Loss of $24.7M, Loss Narrows

For the nine months ended September 30, 2026, Voyager Therapeutics reported a net loss of $77.1 million, an improvement from the $92.3 million loss in the same period of 2025. Collaboration revenue decreased significantly to $9.8 million from $25.0 million year-over-year, while total assets declined to $177.1 million as of September 30, 2026.

Key figure
Net loss $24.7M
4:02 PM ET 8-K
Financial Results Trupanion, Inc. TRUP

Trupanion Financial Results

Trupanion reported Q3 2026 total revenue of $405.6 million, an increase of 11% year-over-year, and net income of $9.3 million. The company also disclosed the repurchase of approximately $25 million of its common stock during the quarter under its existing $100 million authorization.

Term
Q3 2026

“Our third-quarter results were strong, with record cash flow and increased profitability, the seventh consecutive quarter of improvement in retention, and continued progress on our key strategic initiatives. As our business continues to compound, we are investing with discipline in organic growth, and this quarter we also repurchased approximately $25 million of our stock. Both reflect our confidence in the long-term value we are building for pet parents and shareholders.”

Margi Tooth, Chief Executive Officer and President
4:02 PM ET 10-Q
Financial Results Research Frontiers Inc REFR

Research Frontiers Q3 2026 Results: Net Loss of $510K, Loss Widens

Research Frontiers reported a net loss of $1,695,837 for the nine months ended September 30, 2026, compared to a loss of $1,280,021 in the prior year period. Fee income significantly decreased to $299,706 from $1,049,125, while the company maintained a working capital of approximately $0.5 million following a $1.375 million issuance of common stock and warrants.

Key figure
Net loss $510K
4:02 PM ET 10-Q
Financial Results Sintx Technologies, Inc. SINT

Sintx Technologies Q3 2026 Results: Net Loss of $1.59M, Loss Narrows

Sintx Technologies reported a significant increase in total revenue to $3.0 million for the nine months ended September 30, 2026, compared to $0.7 million in the prior year, primarily driven by product revenue. Despite the revenue growth, the company recorded a net loss of $7.1 million for the period, though this was an improvement from the $8.1 million net loss in the same period of 2025.

Key figure
Net loss $1.59M
4:02 PM ET 8-K
Business Update Airbnb, Inc. ABNB

Airbnb Business Update

Airbnb provided an operational update for Q3 2026, highlighting the shipment of over 50 new products and features including expanded 'Connections' and 'Neighborhood' pages. The company also detailed its expansion into hotels, car rentals, and a new exclusive partnership with American Express to list Airbnb stays on AmexTravel.com.

Term
Q3 2026
4:02 PM ET 10-Q
Financial Results Grayscale Bitcoin Mini Trust ETF BTC

Grayscale Bitcoin Mini Trust ETF Q3 2026 Results: Net Income $1.48B, Up 418.4% YoY

Grayscale Bitcoin Mini Trust ETF reported a net increase in net assets from operations of $1.48 billion for the quarter ended September 30, 2026, primarily driven by $1.48 billion in unrealized appreciation of Bitcoin. As of September 30, 2026, the Trust held 63,087.34 Bitcoin with a fair value of $5.27 billion, representing a significant increase from the $4.24 billion held at year-end 2025.

Key figure
Net income $1.48B · +418.4% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.